[go: up one dir, main page]

MX2017005903A - Metodos y composiciones relacionados con el uso de surfactantes bajos en balance hidrofilo-lipofilo (hlb) en la produccion de nanoportadores sinteticos que comprenden un rapalogo. - Google Patents

Metodos y composiciones relacionados con el uso de surfactantes bajos en balance hidrofilo-lipofilo (hlb) en la produccion de nanoportadores sinteticos que comprenden un rapalogo.

Info

Publication number
MX2017005903A
MX2017005903A MX2017005903A MX2017005903A MX2017005903A MX 2017005903 A MX2017005903 A MX 2017005903A MX 2017005903 A MX2017005903 A MX 2017005903A MX 2017005903 A MX2017005903 A MX 2017005903A MX 2017005903 A MX2017005903 A MX 2017005903A
Authority
MX
Mexico
Prior art keywords
hlb
synthetic
nanoporters
rapalogue
hydrophyl
Prior art date
Application number
MX2017005903A
Other languages
English (en)
Other versions
MX383295B (es
Inventor
David H Altreuter
Aaron P Griset
Conlin O'neil
Original Assignee
Selecta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selecta Biosciences Inc filed Critical Selecta Biosciences Inc
Publication of MX2017005903A publication Critical patent/MX2017005903A/es
Publication of MX383295B publication Critical patent/MX383295B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

Se describen composiciones y métodos relacionados con nanoportadores sintéticos que comprenden un material portador hidrófobo, un rapálogo, y un surfactante no iónico con un valor de balance hidrófilo-lipófilo (HLB) menor que o igual a 10.
MX2017005903A 2014-11-05 2015-11-05 Metodos y composiciones relacionados con el uso de surfactantes bajos en balance hidrofilo-lipofilo (hlb) en la produccion de nanoportadores sinteticos que comprenden un rapalogo. MX383295B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462075864P 2014-11-05 2014-11-05
US201462075866P 2014-11-05 2014-11-05
PCT/US2015/059349 WO2016073798A1 (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Publications (2)

Publication Number Publication Date
MX2017005903A true MX2017005903A (es) 2017-06-27
MX383295B MX383295B (es) 2025-03-13

Family

ID=54697646

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2017005903A MX383295B (es) 2014-11-05 2015-11-05 Metodos y composiciones relacionados con el uso de surfactantes bajos en balance hidrofilo-lipofilo (hlb) en la produccion de nanoportadores sinteticos que comprenden un rapalogo.
MX2017005904A MX386982B (es) 2014-11-05 2015-11-05 Métodos y composiciones relacionadas con nanoportadores sintéticos con rapamicina en un estado estable, súper-saturado.
MX2021012273A MX2021012273A (es) 2014-11-05 2017-05-04 Metodos y composiciones relacionadas con nanoportadores sinteticos con rapamicina en un estado estable, super-saturado.
MX2021006698A MX2021006698A (es) 2014-11-05 2017-05-04 Metodos y composiciones relacionados con el uso de surfactantes bajos en balance hidrofilo-lipofilo (hlb) en la produccion de nanoportadores sinteticos que comprenden un rapalogo.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2017005904A MX386982B (es) 2014-11-05 2015-11-05 Métodos y composiciones relacionadas con nanoportadores sintéticos con rapamicina en un estado estable, súper-saturado.
MX2021012273A MX2021012273A (es) 2014-11-05 2017-05-04 Metodos y composiciones relacionadas con nanoportadores sinteticos con rapamicina en un estado estable, super-saturado.
MX2021006698A MX2021006698A (es) 2014-11-05 2017-05-04 Metodos y composiciones relacionados con el uso de surfactantes bajos en balance hidrofilo-lipofilo (hlb) en la produccion de nanoportadores sinteticos que comprenden un rapalogo.

Country Status (23)

Country Link
US (3) US20160128987A1 (es)
EP (6) EP3834823B1 (es)
JP (5) JP7218089B2 (es)
KR (2) KR102601922B1 (es)
CN (5) CN107072964A (es)
AU (4) AU2015342968B2 (es)
BR (3) BR122021025344B1 (es)
CA (2) CA2966852C (es)
CY (1) CY1124418T1 (es)
DK (4) DK3215133T3 (es)
EA (2) EA201790977A1 (es)
ES (4) ES2977158T3 (es)
FI (2) FI3906918T3 (es)
HR (1) HRP20210098T1 (es)
HU (4) HUE067697T2 (es)
IL (7) IL296246A (es)
LT (1) LT3215133T (es)
MX (4) MX383295B (es)
PL (1) PL3215133T3 (es)
PT (1) PT3215133T (es)
RS (1) RS61359B1 (es)
SI (1) SI3215133T1 (es)
WO (2) WO2016073798A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX357630B (es) 2009-05-27 2018-07-17 Selecta Biosciences Inc Nanoportadores sintéticos objetivo con liberación sensible al ph de agentes inmunomoduladores.
EA030813B1 (ru) 2010-05-26 2018-10-31 Селекта Байосайенсиз, Инк Способы генерации антительного иммунного ответа и увеличения местной индукции иммунных цитокинов при использовании синтетических наноносителей, соединенных с адъювантами
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
MX2013012596A (es) 2011-04-29 2014-08-21 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para generar linfocitos t reguladores cd8+.
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
BR112015027279A8 (pt) 2013-05-03 2018-01-30 Selecta Biosciences Inc métodos e composições para acentuar células t reguladoras cd4+
WO2015025538A1 (ja) * 2013-08-20 2015-02-26 サンノプコ株式会社 バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法
US20160074532A1 (en) 2014-09-07 2016-03-17 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
US10125378B2 (en) * 2015-02-17 2018-11-13 San Nopco Ltd. Additive for bioethanol fermentation process and method for producing bioethanol
WO2016176462A1 (en) 2015-04-28 2016-11-03 University Of Central Florida Foundation, Inc. Methods and compositions for theranostic nanoparticles
DK3426285T3 (da) 2016-03-11 2024-08-26 Cartesian Therapeutics Inc Formuleringer og doser af pegyleret uricase
WO2018047443A1 (ja) * 2016-09-09 2018-03-15 花王株式会社 ジカルボン酸結晶及びその製造方法
WO2018064215A1 (en) 2016-09-27 2018-04-05 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
JP2020506890A (ja) 2017-01-07 2020-03-05 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
KR20200086670A (ko) 2017-10-13 2020-07-17 셀렉타 바이오사이언시즈, 인크. 항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물
CA3127799A1 (en) * 2019-01-24 2020-07-30 Generation Bio Co. Close-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response
JP2022531201A (ja) 2019-04-28 2022-07-06 セレクタ バイオサイエンシーズ インコーポレーテッド ウイルス導入ベクターに対する既存の免疫を伴う対象の処置のための方法
CN114206396A (zh) 2019-05-28 2022-03-18 西莱克塔生物科技公司 用于减弱抗病毒转移载体免疫应答的方法和组合物
EP3980784A1 (en) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
EP4048269A1 (en) * 2019-10-21 2022-08-31 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
CN118384281A (zh) 2019-11-08 2024-07-26 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
CA3173734A1 (en) 2020-02-26 2021-09-02 Selecta Biosciences, Inc. Methods and compositions using synthetic nanocarriers comprising immunosuppressant
EP4117631A1 (en) * 2020-03-11 2023-01-18 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
EP4135693A1 (en) 2020-04-14 2023-02-22 Selecta Biosciences, Inc. Methods and compositions for inducing autophagy
WO2022098901A1 (en) 2020-11-04 2022-05-12 Selecta Biosciences, Inc. Compositions for reducing immune responses against immunoglobulin proteases
WO2022150335A1 (en) 2021-01-05 2022-07-14 Selecta Biosciences, Inc. Viral vector dosing protocols
KR102304785B1 (ko) 2021-03-26 2021-09-24 (주)진성티앤피 정밀광학기기의 부품 제조 방법
BR112023020597A2 (pt) 2021-04-09 2023-12-12 Selecta Biosciences Inc Nanocarreadores sintéticos que compreendem um imunossupressante em combinação com agonistas do receptor de il-2 de alta afinidade para aumentar a tolerância imune
EP4323015A4 (en) 2021-04-16 2025-10-22 Askbio Inc RATIONALLY POLYPLOID AAV VIRIONS CROSS THE BLOOD-BRAIN BARRIER AND TRIGGER A REDUCED HUMORAL RESPONSE
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023064350A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
CA3264659A1 (en) 2022-08-11 2024-02-15 Cartesian Therapeutics, Inc. COMPOSITIONS AND PROCESSES ASSOCIATED WITH IMMUNOGLOBULIN PROTEASES AND FUSION THEREOF
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
TWI877967B (zh) * 2023-12-28 2025-03-21 訊聯生物科技股份有限公司 包含小分子核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
AU5068999A (en) 1998-07-31 2000-02-21 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
EP1107783B1 (en) * 1998-09-01 2006-04-05 ELAN CORPORATION, Plc Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
EP1267946A4 (en) 2000-02-28 2008-07-02 Genesegues Inc SYSTEM AND METHOD FOR ENCAPSULATING NANOCAPSULES
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
EP1530456A2 (en) 2002-08-23 2005-05-18 Munich Biotech AG Non-vesicular cationic lipid formulations
CN1886100A (zh) * 2003-11-14 2006-12-27 阿尔萨公司 基于表面活性剂的凝胶作为可注射的持续药物递送载体
US20050260260A1 (en) 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
BRPI0615292A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
ES2765240T3 (es) * 2008-06-16 2020-06-08 Pfizer Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
US20100216804A1 (en) * 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
KR101267813B1 (ko) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
JP6073788B2 (ja) * 2010-09-14 2017-02-01 ナノロジカ アクティエボラーグ 難水溶性医薬及び化粧品有効成分のための過飽和送達媒体
WO2012059936A1 (en) * 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
MX2013012596A (es) * 2011-04-29 2014-08-21 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para generar linfocitos t reguladores cd8+.
CN102793674B (zh) * 2011-05-26 2014-11-26 澳门科技大学 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用
CA2852064A1 (en) 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
TWI439288B (zh) * 2012-10-05 2014-06-01 Univ China Medical 藥用載體及其製備方法與用途
CN102871966B (zh) * 2012-10-19 2013-11-20 东南大学 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法

Also Published As

Publication number Publication date
IL283699A (en) 2021-07-29
KR102656139B1 (ko) 2024-04-11
MX386982B (es) 2025-03-19
EP4356910A3 (en) 2024-05-22
US20160128986A1 (en) 2016-05-12
RS61359B1 (sr) 2021-02-26
EP4360633A3 (en) 2024-05-22
CN107072964A (zh) 2017-08-18
EP4360633A2 (en) 2024-05-01
IL283699B (en) 2022-09-01
DK3215192T3 (da) 2021-05-03
EP3834823A1 (en) 2021-06-16
CN113244191A (zh) 2021-08-13
BR112017008720A2 (pt) 2017-12-19
ES2977158T3 (es) 2024-08-20
PT3215133T (pt) 2021-01-29
ES2865375T3 (es) 2021-10-15
IL280518B (en) 2022-01-01
IL288609B2 (en) 2023-02-01
CN115212186A (zh) 2022-10-21
DK3906918T3 (da) 2024-04-08
EP3906918B1 (en) 2024-01-03
FI3834823T3 (fi) 2024-04-02
IL251622A0 (en) 2017-06-29
IL251620B (en) 2021-02-28
WO2016073799A1 (en) 2016-05-12
MX2017005904A (es) 2017-06-27
US20250152561A1 (en) 2025-05-15
MX383295B (es) 2025-03-13
DK3834823T3 (da) 2024-04-08
IL251620A0 (en) 2017-06-29
IL288609B (en) 2022-10-01
LT3215133T (lt) 2021-02-25
IL280518A (en) 2021-03-01
EP3215133A1 (en) 2017-09-13
AU2021209202A1 (en) 2021-08-19
CA2966852A1 (en) 2016-05-12
MX2021006698A (es) 2021-07-07
US20160128987A1 (en) 2016-05-12
HUE053094T2 (hu) 2021-06-28
EP3834823B1 (en) 2024-01-03
SI3215133T1 (sl) 2021-07-30
JP2021143180A (ja) 2021-09-24
EP3215192B1 (en) 2021-02-17
FI3906918T3 (fi) 2024-04-04
AU2015342968A1 (en) 2017-04-27
CA2966850A1 (en) 2016-05-12
KR20170081659A (ko) 2017-07-12
HRP20210098T1 (hr) 2021-03-05
BR112017008499B1 (pt) 2023-10-03
EP3215192A1 (en) 2017-09-13
EP4356910A2 (en) 2024-04-24
IL295292B2 (en) 2024-10-01
IL251622B (en) 2021-06-30
KR20170081660A (ko) 2017-07-12
BR122021025344B1 (pt) 2024-02-20
AU2015342969A1 (en) 2017-04-27
IL296246A (en) 2022-11-01
WO2016073799A9 (en) 2016-12-08
MX2021012273A (es) 2021-11-12
IL288609A (en) 2022-02-01
CA2966852C (en) 2024-01-02
CN107072965A (zh) 2017-08-18
AU2015342969B2 (en) 2021-05-27
WO2016073798A1 (en) 2016-05-12
EA201790978A1 (ru) 2017-09-29
KR102601922B1 (ko) 2023-11-15
JP6912377B2 (ja) 2021-08-04
ES2846809T3 (es) 2021-07-29
EP3215192A4 (en) 2018-05-02
JP7218089B2 (ja) 2023-02-06
HUE054894T2 (hu) 2021-10-28
PL3215133T3 (pl) 2021-06-14
JP2017537081A (ja) 2017-12-14
HUE066099T2 (hu) 2024-07-28
CA2966850C (en) 2024-03-26
IL295292A (en) 2022-10-01
AU2015342968B2 (en) 2021-05-27
AU2021209204A1 (en) 2021-08-19
IL295292B1 (en) 2024-06-01
EP3906918A1 (en) 2021-11-10
AU2021209202B2 (en) 2023-11-30
CY1124418T1 (el) 2022-07-22
EP3215133B1 (en) 2020-10-28
ES2977259T3 (es) 2024-08-21
EA201790977A1 (ru) 2017-10-31
BR112017008499A2 (pt) 2017-12-26
CN107072965B (zh) 2021-05-11
HUE067697T2 (hu) 2024-11-28
DK3215133T3 (da) 2021-02-01
JP2017533243A (ja) 2017-11-09
JP2022173236A (ja) 2022-11-18
JP2023169893A (ja) 2023-11-30
CN115212187A (zh) 2022-10-21

Similar Documents

Publication Publication Date Title
MX2017005903A (es) Metodos y composiciones relacionados con el uso de surfactantes bajos en balance hidrofilo-lipofilo (hlb) en la produccion de nanoportadores sinteticos que comprenden un rapalogo.
AU366476S (en) Bottle
GB2546432A (en) Apertured fibrous structures and methods for making same
BR112017006137A2 (pt) formulação que contém biotensoativo
BR112017004573A2 (pt) composições detergentes contendo um tensoativo ramificado
AR100374A1 (es) Composición de limpieza antimicrobiana
AR104725A1 (es) Composiciones surfactantes y detergentes que contienen glicerina etoxilada
MX375352B (es) Reguladores de nrf2.
MX2018011099A (es) Granulado que comprende un vehiculo solido inorganico con al menos un biosurfactante contenido en el mismo.
MX2016014241A (es) Composicion de limpieza que contiene una polieteramina.
EP3164111A4 (en) Surfactant-stripped micelle compositions with high cargo to surfactant ratio
MX2016013890A (es) Composicion de champu que comprende matriz de gel e histidina.
MX2019002880A (es) Proceso para elaborar una composicion que comprende particulas de suministro de agente benefico.
EP3508269A4 (en) TENSIDE COMPOSITION
CL2019003063A1 (es) Heteroaril fenil aminoquinolinas y sus análogos.
BR112017002090A2 (pt) formulação de fator viii
AR101880A1 (es) Composición blanqueadora
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
CL2017000613A1 (es) Proceso en seco para preparar un material que contiene carbonato de metal alcalinotérreo modificado de superficie
MX2023011771A (es) Particulas ocultas para usarse en composiciones granulares para el cuidado de la ropa.
MX2016003543A (es) Estructuras fibrosas mejoradas que contienen surfactantes y metodos para fabricarlas.
EP3467079A4 (en) TENSIDE COMPOSITION
BR112017013787A2 (pt) Composições de microesfera de gás lipídio- encapsulado e métodos relacionados
CO2017004809A2 (es) Composiciones de triptamidas
MX2016009402A (es) Premezcla de abrillantador fluorescente.